Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.46 |
| ▸ | ME3 | Q16798 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CASR | P41180 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | GRK2 | P25098 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | QPCT | Q16769 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13506075 | 0.89 | ITGB3 (0.47) | ITGB3ITGA2BNPC1RAB9AMCL1 | |
| SCHEMBL14780920 | 0.89 | ITGB3 (0.50) | ITGB3ITGA2BNPC1RAB9AMCL1 | |
| SCHEMBL3485750 | 0.87 | GPR119 (0.47) | NPC1RAB9AMCL1GPR119ME3 | |
| SCHEMBL10316354 | 0.86 | ITGB3 (0.54) | ITGB3ITGA2BNPC1GPR119ME3 | |
| SCHEMBL3486912 | 0.82 | GPR119 (0.73) | GPR119MAPTALDH1A1 | |
| SCHEMBL17746117 | 0.81 | TDP1 (0.55) | GPR119ME3MAPTME2ME1 | |
| SCHEMBL11853729 | 0.81 | ITGB3 (0.57) | ITGB3ITGA2BNPC1RAB9AMCL1 | |
| SCHEMBL10316358 | 0.81 | ITGB3 (0.49) | ITGB3ITGA2BNPC1GPR119ME3 | |
| SCHEMBL3486756 | 0.80 | GPR119 (0.49) | GPR119ME3 | |
| SCHEMBL21624841 | 0.80 | USP2 (0.64) | ITGB3ITGA2BNPC1RAB9AMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178681-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS, CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20100075987-A1 | ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. | 2010-03-25 | — | — | US | disclosed |
| US-20100029688-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075987-A1 | ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR27, FFAR2 | ITGB3 4260/4885ITGA2B 3677/4885NPC1 1387/4885 |
| US-20100029688-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR139, GPR27 | ITGB3 4306/4885ITGA2B 3813/4885NPC1 1184/4885 |
| US-20120178681-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS, CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR139, GPR27 | ITGB3 4291/4885ITGA2B 3839/4885NPC1 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.